Table 1:
Lipidomic studies on biofluids reporting diagnostic lipid signatures
| Cancer type | Control samples | Cancer samples | MS Platform | Biofluid | Lipids altered | Reference |
|---|---|---|---|---|---|---|
| Ovarian | 212 | 211 | LC/ESI/MS/MS | Plasma | PPE(16:0,18:1) LPC15:0 LPA18:2 PPE(18:0,22:6) |
Shan et al, 2012 [1] |
| Liver | 90 | 82 | UPLC-MS | Serum | LPC16:0 LPC18:0 PS16:0 PC18:0 |
Wang et al, 2012 [2] |
| Liver | 37 | 37 | GC-MS | Plasma | 18:2n-6 18:1n-9 20:4n-6 16:0 |
Qiu et al, 2015 [3] |
| Lung | 495 | 58 | FTICR-MS | Serum | SM(16:0,16:1) LPC18:1 LPC20:4 LPC20:3 LPC22:6 |
Guo et al, 2012 [4] |
| Lung | 147 | 199 | ESI-MS | Plasma | LPE18:1 CE18:2 ePE40:4 SM22:0 |
Yu et al, 2017 [5] |
| Prostate | 76 | 57 | Q-TOF-MS | Plasma | ePC38:5 PC40:3 PC42:4 |
Patel et al, 2014 [6] |
| Breast | 74 (inc. 40 non-malignant lesions) | 40 | GC-MS | Serum | 16:0 18:0 18:2 18:3 20:5 22:5 |
Lv et al, 2012 [7] |
| Colorectal | 84 | 63 | GC-MS | Plasma | 10:0 | Crotti et al, 2016 [8] |